Figure 4. FACS analysis of CD11b and CD45 immunoreactive microglia/macrophages and CD3 positive T cells in the lumbar spinal cord of C57BL6/J naïve and EAE mice.

Further quantitative results in Supplementary Tables S2 and S3. The spinal cord was dissected out during the flare of the disease (day 20). The treatment with vehicle or R-flurbiprofen (10 mg/kg/day, drinking water) was preventive (A, B) or semi-therapeutic (C, D).

1. Exemplary scatter dot plots of CD45⁺ cells, subsequently gated for CD11b versus CD206 (marker for M2-like microglia/macrophages) and CD11b versus CXCR3 (high in microglia). CD11b-high cells were increased in the vehicle group, but not in R-flurbiprofen treated mice.
2. Quantitative results of the blue and yellow gates of (A). (n = 3, two-way ANOVA, post hoc Bonferroni versus naïve for ‘treatment’ P-values *¹0.0093, *²0.005).
3. Exemplary density plots of CD11b⁺ cells subsequently gated for MHC-II (marker for antigen presenting cells) versus CXCR3 and CD36 (scavenger receptor class B, marker for M2-like) versus CD206. CD36⁺ M2-like cells were strongly reduced in the vehicle group.
4. Quantitative result for CD3⁺ T cells subsequently gated for CD4 versus CD25. CD4⁺CD25⁺ T cells (likely to be Tregs) were higher in the R-flurbiprofen group (n = 5, two-way ANOVA, post hoc Dunnett versus naïve for ‘treatment’ *P = 0.0056).